Stijn C van de Laar
Overview
Explore the profile of Stijn C van de Laar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
12
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van de Laar S, Wiltschut B, Oudmaijer C, Muller K, Massey E, Porte R, et al.
Clin Kidney J
. 2025 Feb;
18(2):sfae374.
PMID: 39917536
Background: Kidney exchange programmes (KEPs) have revolutionized living donor kidney transplantation (LDKT) by enabling transplants for patients with HLA- or ABO-incompatible donors. However, the implications for donors participating in KEPs,...
2.
van de Laar S, de Weerd A, Bemelman F, Idu M, de Vries A, Alwayn I, et al.
Clin J Am Soc Nephrol
. 2025 Jan;
20(3):440-450.
PMID: 39879095
No abstract available.
3.
van de Laar S, Lafranca J, Minnee R, Papalois V, Dor F
J Clin Med
. 2022 Mar;
11(6).
PMID: 35329945
Studies have been carried out to investigate the effect of a prolonged cold ischaemia time (CIT) on the outcomes of living donor kidney transplantation (LDKT). There is no clear consensus...
4.
van de Laar S, Schouten G, IJzermans J, Minnee R
Transplant Proc
. 2021 Aug;
53(7):2122-2132.
PMID: 34412911
Background: The effect of mannitol usage during kidney donation and kidney transplantation is still unclear. Therefore, we performed a systematic review and meta-analysis to research the difference in graft function...
5.
van de Laar S, Robb M, Hogg R, Burnapp L, Papalois V, Dor F
Ann Surg
. 2021 Aug;
274(5):859-865.
PMID: 34334648
Objective: To assess the impact of CIT on living donor kidney transplantation (LDKT) outcomes in the UKLKSS versus outside the scheme. Background: LDKT provides the best treatment option for end-stage...